Targeting both tumour-associated CXCR2⁺ neutrophils and CCR2⁺ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

Abstract

Dual targeting of CCR2⁺ TAM and CXCR2⁺ TAN improves antitumour immunity and chemotherapeutic response in PDAC compared with either strategy alone.